Hormonal Effects of Gonadotropin-Releasing Hormone (GnRH) Agonist in the Human Male. III. Effects of Long Term Combined Treatment with GnRH Agonist and Androgen*

1985 ◽  
Vol 60 (5) ◽  
pp. 998-1003 ◽  
Author(s):  
S. BHASIN ◽  
D. HEBER ◽  
B. S. STEINER ◽  
D. J. HANDELSMAN ◽  
R. S. SWERDLOFF
2014 ◽  
Vol 63 (2) ◽  
pp. 6-11
Author(s):  
Lyudmila Vladimirona Tkachenko ◽  
Nataliya Ivanovna Sviridova

The aim of this study was to evaluate the efficacy of an agonist of gonadotropin-releasing hormone Buserilin in the treatment of patients with endometriosis in combination with endometrial hyperplasia. We conducted a clinical and laboratory examination and treatment of 108 patients aged 41 to 52 years old suffering from endometriosis varying degrees of prevalence in conjunction with endometrial hyperplasia. The results obtained suggest a scientifically sound complex treatment of patients with endometriosis on the background of endometrial hyperplasia with a GnRH agonist Buserilin-depo in the postoperative period, followed by the appointment of progestogens or combiened oral contraceptives as a long-term program management of patients to prevent relapse and re-operative treatment.


1989 ◽  
Vol 123 (1) ◽  
pp. 83-91 ◽  
Author(s):  
K.-L. Kolho ◽  
I. Huhtaniemi

ABSTRACT The acute and long-term effects of pituitary-testis suppression with a gonadotrophin-releasing hormone (GnRH) agonist, d-Ser(But)6des-Gly10-GnRH N-ethylamide (buserelin; 0·02, 0·1, 1·0 or 10 mg/kg body weight per day s.c.) or antagonist, N-Ac-d-Nal(2)1,d-p-Cl-Phe2,d-Trp3,d-hArg(Et2)6,d-Ala10-GnRH (RS 68439; 2 mg/kg body weight per day s.c.) were studied in male rats treated on days 1–15 of life. The animals were killed on day 16 (acute effects) or as adults (130–160 days; long-term effects). Acutely, the lowest dose of the agonist decreased pituitary FSH content and testicular LH receptors, but with increasing doses pituitary and serum LH concentrations, intratesticular testosterone content and weights of testes were also suppressed (P< 0·05–0·01). No decrease was found in serum FSH or in weights of accessory sex organs even with the highest dose of the agonist, the latter finding indicating continuing secretion of androgens. The GnRH antagonist treatment suppressed pituitary LH and FSH contents and serum LH (P< 0·05–0·01) but, as with the agonist, serum FSH remained unaltered. Testicular testosterone and testis weights were decreased (P <0·01) but testicular LH receptors remained unchanged. Moreover, the seminal vesicle and ventral prostate weights were reduced, in contrast to the effects of the agonists. Pituitary LH and FSH contents had recovered in all adult rats treated neonatally with agonist and there was no effect on serum LH and testosterone concentrations or on fertility. In contrast, in adult rats treated neonatally with antagonist, weights of testis and accessory sex organs remained decreased (P <0·01–0·05) but hormone secretion from the pituitary and testis had returned to normal except that serum FSH was increased by 80% (P <0·01). Interestingly, 90% of the antagonist-treated animals were infertile. It is concluded that treatment with a GnRH agonist during the neonatal period does not have a chronic effect on pituitary-gonadal function. In contrast, GnRH antagonist treatment neonatally permanently inhibits the development of the testis and accessory sex organs and results in infertility. Interestingly, despite the decline of pituitary FSH neonatally, neither of the GnRH analogues was able to suppress serum FSH values and this differs from the concomitant changes in LH and from the effects of similar treatments in adult rats. Journal of Endocrinology (1989) 123, 83–91


2018 ◽  
Vol 31 (2) ◽  
pp. 190
Author(s):  
Jenny Sadler Gallagher ◽  
Stacey A. Missmer ◽  
Mark D. Hornstein ◽  
Marc R. Laufer ◽  
Catherine M. Gordon ◽  
...  

2007 ◽  
Vol 88 ◽  
pp. S126
Author(s):  
E.B. Johnston-MacAnanny ◽  
C.A. Benadiva ◽  
L.J. Siano ◽  
J.C. Nulsen ◽  
D.B. Maier ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document